Cite
HARVARD Citation
Zandberg, D. et al. (2019). Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. European journal of cancer. pp. 142-152. [Online].